Roka Bioscience (ROKA) 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 08, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'ROKA	'
Entity Registrant Name	'ROKA BIOSCIENCE, INC.	'
Entity Central Index Key	'0001472343	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	17,653,797

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$26,013	$32,728
Trade accounts receivable, net of $0 allowance for doubtful accounts	566	277
Inventories	4,706	3,879
Deferred tax assets	'	3,135
Prepaid expenses and other current assets	3,819	2,437
Total current assets	35,104	42,456
Property and equipment, net	13,258	14,510
Intangible assets, net	1,260	1,344
Goodwill	360	360
Other assets	2,823	444
Total assets	52,805	59,114
Current Liabilities:	'	'
Accounts payable	882	1,226
Short-term deferred payments	521	339
Notes payable, current	9,800	4,919
Accrued expenses	5,487	2,381
Total current liabilities	16,690	8,865
Deferred payments	3,216	3,205
Convertible preferred stock warrant liability	1,142	212
Deferred tax liabilities	40	40
Other long-term liabilities	342	339
Total liabilities	21,430	12,661
Commitments and Contingencies (See Note 9)	'	'
Stockholders' Deficit:	'	'
Common stock, $0.001 par value: 141,963,421 shares of Series A common stock authorized; 1,268,846 and 1,181,936 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively; 292,414 shares of Series B common stock authorized; 3,129 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	9	8
Additional paid-in capital	20,158	19,422
Accumulated deficit	-116,490	-100,774
Total stockholders' deficit	-96,323	-81,344
Total liabilities and stockholders' deficit	52,805	59,114
Series B Convertible Preferred Stock [Member]	'	'
Current Liabilities:	'	'
Convertible preferred stock, value	33,450	33,450
Series C Convertible Preferred Stock [Member]	'	'
Current Liabilities:	'	'
Convertible preferred stock, value	15,836	15,836
Series D Convertible Preferred Stock [Member]	'	'
Current Liabilities:	'	'
Convertible preferred stock, value	43,272	43,272
Series E Convertible Preferred Stock [Member]	'	'
Current Liabilities:	'	'
Convertible preferred stock, value	$35,140	$35,239

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$0	$0
Convertible preferred stock, shares issued	0	'
Common stock par value	$0.00	$0.00
Series B Convertible Preferred Stock [Member]	'	'
convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	39,680,000	39,680,000
Convertible preferred stock, shares issued	37,200,000	37,200,000
Convertible preferred stock, shares outstanding	37,200,000	37,200,000
Convertible preferred stock, liquidation value	37,200	37,200
Series C Convertible Preferred Stock [Member]	'	'
convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	12,090,672	12,090,672
Convertible preferred stock, shares issued	12,090,672	12,090,672
Convertible preferred stock, shares outstanding	12,090,672	12,090,672
Convertible preferred stock, liquidation value	16,020	16,020
Series D Convertible Preferred Stock [Member]	'	'
convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	32,511,979	32,511,979
Convertible preferred stock, shares issued	32,511,979	32,511,979
Convertible preferred stock, shares outstanding	32,511,979	32,511,979
Convertible preferred stock, liquidation value	47,500	47,500
Series E Convertible Preferred Stock [Member]	'	'
convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	33,601,367	33,601,367
Convertible preferred stock, shares issued	32,934,700	32,934,700
Convertible preferred stock, shares outstanding	32,934,700	32,934,700
Convertible preferred stock, liquidation value	$41,992	$41,992
Series A Common Stock [Member]	'	'
Common Stock, shares authorized	141,963,421	141,963,421
Common Stock, shares issued	1,268,846	1,268,846
Common Stock, shares outstanding	1,181,936	1,181,936
Series B Common Stock [Member]	'	'
Common Stock, shares authorized	292,414	292,414
Common Stock, shares issued	3,129	3,129
Common Stock, shares outstanding	3,129	3,129

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	$1,390	$671	$2,218	$937
Operating expenses:	'	'	'	'
Cost of revenue	1,573	1,676	2,838	3,549
Research and development	2,227	1,945	4,069	3,697
Selling, general and administrative	4,548	4,275	9,596	8,533
Amortization of intangible assets	42	42	84	84
Total operating expenses	8,390	7,938	16,587	15,863
Loss from operations	-7,000	-7,267	-14,369	-14,926
Other income (expense):	'	'	'	'
Change in fair value of financial instruments	41	-594	-562	-575
Interest income (expense), net	-378	-80	-768	-154
Loss before income taxes	-7,337	-7,941	-15,699	-15,655
Income tax provision (benefit)	12	1	17	1
Net loss and comprehensive loss	($7,349)	($7,942)	($15,716)	($15,656)
Net Loss per Common Share:	'	'	'	'
Basic and diluted	($11.28)	($15.96)	($24.88)	($34.10)
Weighted average common shares outstanding used in computing net loss per common share:	'	'	'	'
Basic and diluted	651,598	486,184	631,620	453,768

Condensed_Statement_of_Convert

Condensed Statement of Convertible Preferred Stock and Stockholders' Deficit (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Beginning Balance, Amount at Dec. 31, 2012	($69,728)	$100,537	$8	$1,460	($71,196)
Beginning Balance, Shares at Dec. 31, 2012	'	84,927,615	683,428	'	'
Issuance of Series E convertible preferred stock	'	35,094	'	'	'
Issuance of Series E convertible preferred stock, Shares	'	32,934,700	'	'	'
Conversion of convertible preferred stock into Common Stock	17,206	-17,206	'	17,206	'
Conversion of convertible preferred stock into Common Stock, Shares	'	-3,296,082	53,688	'	'
Issuance of restricted shares to employees	'	'	439,300	'	'
Exercise of options for Common Stock	20	'	'	20	'
Exercise of options for Common Stock, Shares	'	'	8,649	'	'
Exercise of warrants for Series A Preferred Stock	'	9,412	'	'	'
Exercise of warrants for Series A Preferred Stock, Shares	'	171,118	'	'	'
Stock-based compensation expense	696	'	'	696	'
Deemed dividends	40	-40	'	40	'
Net loss	-29,578	'	'	'	-29,578
Ending Balance, Amount at Dec. 31, 2013	-81,344	127,797	8	19,422	-100,774
Ending Balance, Shares at Dec. 31, 2013	'	114,737,351	1,185,065	'	'
Series E issuance costs	1,368	-99	'	'	'
Exercise of options for Common Stock	213	'	1	212	'
Exercise of options for Common Stock, Shares	'	'	86,909	'	'
Stock-based compensation expense	524	'	'	524	'
Net loss	-15,716	'	'	'	-15,716
Ending Balance, Amount at Jun. 30, 2014	($96,323)	$127,698	$9	$20,158	($116,490)
Ending Balance, Shares at Jun. 30, 2014	'	114,737,351	1,271,974	'	'

Condensed_Statement_of_Convert1

Condensed Statement of Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) (Preferred Stock [Member], USD $)	Dec. 31, 2013
Preferred Stock [Member]	'
Issuance of Series E convertible preferred stock for cash, per share	$1.27

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities	'	'
Net loss	($15,716)	($15,656)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	1,328	1,179
Change in fair value of financial instruments	562	575
Loss on disposal of property and equipment	98	'
Provisions for inventory	81	707
Share-based compensation expense	524	354
Non-cash interest expense	533	164
Changes in operating assets and liabilities:	'	'
Accounts receivable	-349	-214
Inventories	-908	-637
Prepaid expenses and other assets	494	-81
Accounts payable and accrued expenses	-183	-621
Deferred taxes	3,135	'
Other liabilities	3	14
Net cash used in operating activities	-10,398	-14,216
Cash flows from investing activities	'	'
Purchases of property and equipment, net of sales	-63	-1,971
Net cash used in investing activities	-63	-1,971
Cash flows from financing activities	'	'
Net proceeds from issuance of convertible preferred stock and warrants	-99	25,000
Net proceeds from issuance of debt and warrants	5,000	'
Net proceeds from exercise of stock options	213	18
Issuance costs related to planned issuance of common stock	-1,368	'
Net cash provided by financing activities	3,746	25,018
Net change in cash and cash equivalents	-6,715	8,831
Cash and cash equivalents, beginning of period	32,728	17,314
Cash and cash equivalents, end of period	$26,013	$26,145

Business_Overview

Business Overview	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Business Overview	'
	1. BUSINESS OVERVIEW
	Business
	Roka Bioscience, Inc. (“Roka” or “the Company”) is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens. The Company was established in September 2009 through the acquisition of industrial testing assets and technology from Gen-Probe Incorporated, which was subsequently acquired by Hologic, Inc. (herein referred to as “Gen-Probe”).
	The Company has limited capital resources and has experienced negative cash flows from operations and has incurred net losses since inception. The Company expects to continue to experience negative cash flows from operations and incur net losses in the near term as it devotes substantially all of its efforts on commercial product launch and continued product development. The Company’s business is subject to significant risks and its ability to successfully develop, manufacture and commercialize proprietary products is dependent upon many factors including, but not limited to, risks and uncertainties associated with the supply of molecular diagnostic instruments (“Atlas instruments”) and materials, product development, manufacturing scale-up, attracting and retaining key personnel, customer acceptance as well as competition. As discussed in Note 18, the Company raised approximately $53.4 million in net proceeds from its initial public offering in July 2014. The Company may need to raise additional capital through the sale of equity and/or debt securities in the future. There is no assurance that the Company will be able to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding preferred and common stock. Issued debt securities may contain covenants and limit the Company’s ability to pay dividends or make other distributions to stockholders. In addition, the Company’s debt agreements contain material adverse change clauses which allows the lenders to call the debt based on subjective factors regarding the Company’s business and performance which may be considered a material adverse change.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying unaudited condensed financial statements of Roka Bioscience, Inc. have been prepared by the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these condensed notes to the unaudited financial statements should be read in conjunction with the 2013 audited financial statements and notes thereto prepared in accordance with U.S. GAAP. The unaudited financial statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited financial statements for the year ended December 31, 2013. The condensed Balance Sheet as of December 31, 2013 was derived from the Company’s audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. There have been no changes to the Company’s significant accounting policies since December 31, 2013. The unaudited financial statements reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods presented. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other future annual or interim period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited financial statements included in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission (the “SEC”) on July 16, 2014 (the “Prospectus”).
	Previously, the Company calculated the fair value of its convertible preferred stock warrants outstanding using a time period based upon an estimated liquidation date. During the three months ended March 31, 2014, it was determined that a liquidation date cannot be reasonably estimated, nor do they automatically expire upon a liquidation event such as an initial public offering, and consequently the life used to value these warrants should reflect the expiration date of each warrant. As a result of this change in estimate, during the three months ended March 31, 2014 the Company recognized the following prior period expenses: approximately $435,000 related to the change in fair value of warrants, approximately $26,000 of interest expense and approximately $77,000 of other expenses as a result of the change in calculation of the fair value of warrants. Additionally, this change in valuation resulted in a reduction of notes payable of approximately $77,000, deemed to be an additional debt discount which will be accreted to notes payable over the life of the loan with a corresponding charge to interest expense. Furthermore, the change in valuation resulted in an increase in our deferred financing costs of $77,000 which was expensed in the six months ended June 30, 2014. Management does not believe this adjustment is material to the current or prior periods.
	Common A and Common B Reverse Stock Split
	In July 2014, the Company’s board of directors authorized and the Company’s shareholders approved an 11.04:1 reverse stock split of the Company’s Class A common stock (“Common A”) and Class B common stock (“Common B”), together referred to as “Common Stock”, effective on July 3, 2014. In addition, effective on the date of the Common Stock reverse stock split, the conversion ratio of Series B Convertible Preferred Stock (“Series B”), Series C Convertible Preferred Stock (“Series C”), Series D Convertible Preferred Stock (“Series D”) and Series E Convertible Preferred Stock (“Series E”) collectively referred to as “Convertible Preferred Stock” was adjusted by a factor of 11.04. Each share of Series B, Series C and Series E will be convertible into approximately 0.0906 shares of Common Stock and each share of Series D will be convertible into approximately 0.0937 shares of Common Stock. The Company’s historical share and per share information have been retroactively adjusted to give effect to this reverse split and corresponding change in conversion ratio.
	New Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. ASU 2014-09 provides companies with two implementation methods. Companies can choose to apply the standard retrospectively to each prior reporting period presented (full retrospective application) or retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early application is not permitted. The Company is currently in the process of evaluating the impact this new guidance will have on the Company.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2014
Cash And Cash Equivalents [Abstract]	'
Cash and Cash Equivalents	'
	3. CASH AND CASH EQUIVALENTS
	The Company’s entire balance of cash and cash equivalents as of June 30, 2014 was held in demand accounts with one financial institution, which potentially subjects the Company to significant concentrations of credit risk.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	4. INVENTORIES
	The following table provides details of the Company’s net inventories (amounts in thousands):
		As of June 30,		As of December 31,
		2014		2013
	Raw materials	$	1,674	$	1,846
	Work in process		93		—
	Finished goods		2,939		2,033
		$	4,706	$	3,879

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	5. PROPERTY AND EQUIPMENT
	The following table provides details of the Company’s property and equipment (amounts in thousands):
		As of June 30,			As of December 31,
		2014			2013
	Atlas instruments	$	10,192		$	10,330
	Manufacturing equipment		2,801			2,801
	Laboratory equipment		2,967			2,923
	Computer and office equipment		1,427			1,388
	Leasehold improvements		1,272			1,272
	Software		1,113			1,106
	Total property and equipment	$	19,772		$	19,820
	Less: Accumulated depreciation		(6,514	)		(5,310	)
	Total	$	13,258		$	14,510
	Atlas instruments include instruments intended for placement with customers and instruments placed with customers under lease agreements. As of June 30, 2014 and December 31, 2013, the cost of Atlas instruments, which represents equipment on lease or held for lease, was $9.3 million and $9.8 million, respectively, net of accumulated depreciation of $0.9 million and $0.5 million, respectively.
	Expenses for depreciation of property and equipment were incurred as follows (amounts in thousands):
		For the Three Months Ended June 30,						For the Six Months Ended June 30,
		2014			2013			2014		2013
	Depreciation expense	$	625		$	558		$	1,244	$	1,095

Accrued_Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2014
Payables And Accruals [Abstract]	'
Accrued Expenses	'
	6. ACCRUED EXPENSES
	The following table provides details of the Company’s accrued expenses (amounts in thousands):
		As of June 30,		As of December 31,
		2014		2013
	Employee related	$	1,217	$	888
	Professional services		963		1,328
	Other		3,307		165
	Total accrued expenses	$	5,487	$	2,381
	Included within Professional services and Other in the above table is approximately $430,000 and $526,000 for issuance costs related to the planned issuance of common stock as of June 30, 2014 and December 31, 2013, respectively. Included within Other as of June 30, 2014 in the above table is $2.5 million related to a payment due to Gen-Probe pursuant to the amendment to the license agreement discussed below in Note 9.

Deferred_Payments

Deferred Payments	6 Months Ended
	Jun. 30, 2014
Other Liabilities Disclosure [Abstract]	'
Deferred Payments	'
	7. DEFERRED PAYMENTS
	In May 2011, the Company entered into a supply agreement with Gen-Probe, a former related party, to purchase Atlas instruments. Pursuant to the terms of the agreement, the Company can defer up to one half of the purchase price for up to 54 months from the date of delivery. The deferred amounts do not bear interest, and the Company has determined that ASC 835-30 Imputation of interest (“ASC-835”) applies. Accordingly, the Company recorded the imputed interest component as a reduction of the deferred payment and as a reduction of the asset cost. The supply agreement provides for variable repayment terms based on a percentage of net sales as defined in the agreement, and the Company has estimated its net sales in determining amounts due for the 54 month term. The following table summarizes the amounts deferred under this agreement (amounts in thousands):
		As of June 30,			As of December 31,
		2014			2013
	Current
	Deferred payments, gross	$	923		$	759
	Imputed interest		(402	)		(420	)
	Deferred payments, net	$	521		$	339
	Long-term
	Deferred payments, gross	$	3,868		$	4,053
	Imputed interest		(652	)		(848	)
	Deferred payments, net	$	3,216		$	3,205
	The Company estimated the interest rate implicit in the extended payment terms by considering the rate at which it could obtain financing of a similar nature from other sources at the date of the transaction, as well as prevailing rates for similar debt instruments of issuers with similar credit ratings, the estimated effective interest rate used, ranges from 9.9% to 11.2%.
	In the three months and six months ended June 30, 2014, the Company recorded approximately $106,000 and $214,000, respectively, and in the three months and six months ended June 30, 2013, the Company recorded approximately $84,000 and $164,000, respectively, as non-cash interest expense related to the deferred payments pursuant to the supply agreement with Gen-Probe.

Notes_Payable

Notes Payable	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Notes Payable	'
	8. NOTES PAYABLE
	In November 2013, the Company entered into two loan and security agreements, under which the Company may borrow up to an aggregate of $15.0 million in three separate $5.0 million tranches upon meeting certain provisions. The first tranche is subject to the terms and conditions of the loan and security agreement entered into with Comerica Bank (“Comerica”) and the second and third tranches are subject to the terms and conditions of the loan and security agreement entered into with TriplePoint Capital LLC (“TriplePoint”).
	The loan and security agreement with Comerica (the “Comerica Loan”), provides for borrowing of up to $5.0 million and accrues interest at Comerica’s Prime Referenced Rate (as defined in the loan agreement with Comerica), subject to a floor of the daily adjusting LIBOR rate plus 2.5%, plus 3.15%. As of June 30, 2014, the rate was 6.4%. The loan is interest-only until June 1, 2015 and matures in 42 months. After the 18-month interest-only period, the Company will make 23 consecutive monthly payments which will consist of accrued interest and equal principal payments in accordance with a 30-month amortization schedule. On the 24th month following the interest only period, the Company will make a lump sum payment for the remaining outstanding principal and interest due.
	The loan and security agreement with TriplePoint (the “TriplePoint Loan”), provides for borrowings up to $10.0 million. The Company may borrow up to $5.0 million in the second tranche, consisting of one or more term loan advances, before March 31, 2014 and if the Company has generated at least $10.0 million in revenue between November 21, 2013 and September 30, 2014, it would be eligible to borrow up to an additional $5.0 million in the third tranche, consisting of one or more term loan advances, until December 31, 2014. Borrowings under the TriplePoint Loan will accrue interest at the Prime Rate plus 5.75%, but not less than 9.0%. Each tranche under the TriplePoint Loan is repayable over 36 months from the borrowing date with an interest-only period of nine months for the second tranche and six months for the third tranche (or 12 months for each tranche upon election by the Company to extend the interest only period), and equal monthly installments of principal and interest over the remaining term of the loan after the interest only period. If the Company extends the interest only period, the TriplePoint Loan will accrue interest at the Prime Rate plus 6.25%, but not less than 9.5%.
	The loan agreements do not contain any financial covenants. However, the agreements contain various covenants that limit the Company’s ability to engage in specified types of transactions, including limiting the Company’s ability to; sell, transfer, lease or dispose of certain assets; engage in certain mergers and consolidations; incur debt or encumber or permit liens on certain assets, make certain restricted payments, including paying dividends on, or repurchasing or making distributions with respect to, the Company’s Common Stock; and enter into certain transactions with affiliates. Additionally, the Company has pledged substantially all of its assets except intellectual property as collateral for the loans.
	Upon the closing of the loan and security agreements, the Company borrowed $5.0 million from Comerica. In connection with the closing of the loan and security agreements, the Company issued warrants to Comerica and TriplePoint to purchase up to an aggregate of 352,941 shares of Series E with an exercise price of $1.28.
	In connection with the Comerica Loan, the Company recorded the liability for the note as $4.9 million, net of expenses paid to Comerica and the value of the warrant issued to Comerica. The difference between the liability recorded and the face value of the note will be accreted to Notes payable over the term of the loan with a corresponding charge to interest expense. Additionally, the Company incurred debt issuance costs of approximately $76,000 which were capitalized within Other assets on the Balance Sheet and will be amortized to Interest expense over the life of the loan using the interest method.
	In connection with the TriplePoint Loan, the Company incurred approximately $153,000 of debt issuance costs which were capitalized with Other assets on the Balance Sheet and will be amortized to Interest expense over the term the funds are available to Roka to be borrowed.
	In March 2014, the Company borrowed $5.0 million from TriplePoint under the second tranche and elected to repay the loan based upon the extended interest-only period noted above, therefore, such borrowings will accrue interest at a rate of 9.5%. In connection with the borrowings under the second tranche, the TriplePoint warrants became exercisable for an additional 156,863 shares of Series E. Furthermore, the Company recorded the liability for the note as $5.0 million less the value of the associated warrant of approximately $135,000. The difference between the liability recorded and the face value of the note will be accreted to Notes payable over the term of the loan with a corresponding charge to interest expense. In the event of additional borrowings under the third tranche, the TriplePoint warrants will become exercisable for up to an additional 156,863 shares of Series E.
	As of June 30, 2014, the Company has classified the outstanding debt as a current liability due to a material adverse change clause within the loan agreements which allow Comerica and TriplePoint to call the debt based on subjective factors regarding the Company’s business and performance.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	9. COMMITMENTS AND CONTINGENCIES
	Operating leases
	The Company has not entered into any new operating leases or amended any operating leases during the six months ended June 30, 2014.
	Contractual obligations
	During the six months ended June 30, 2014, there have been no significant changes to the Company’s contractual obligations as disclosed in the Company’s most recent audited financial statements except as described below.
	In June 2014, the Company entered into an amendment to its license agreement with Gen-Probe, a former related party, which grants the Company a two-year option to reduce the royalty rate it pays to Gen-Probe in exchange for an option payment of $2.5 million. The option is exercisable at the Company’s discretion if it raises less than $55.0 million in net proceeds from an IPO and is automatically exercised if it raises at least $55.0 million in net proceeds from an IPO. The option would be exercised simultaneously with the closing of an IPO. Upon exercise of such option to reduce the royalty rate that the Company pays to Gen-Probe, the Company is obligated to make the following payments to Gen-Probe: (i) within ten days of the closing of an IPO, the Company would issue 865,063 shares of common stock to Gen-Probe, (ii) within ten days of the closing of an IPO, the Company would make a cash payment of $8.0 million using a portion of the net proceeds from such IPO, (iii) on January 1, 2018, the Company would make a cash payment of $5.0 million and (iv) on January 1, 2020, the Company would make a cash payment of $5.0 million. In addition, the Company may make additional milestone payments of up to $6.0 million to further reduce the royalty rate. Such payments are required to be made upon meeting certain revenue milestones or may be made at the election of the Company prior to meeting the revenue milestones. The aggregate payments will be recorded as an addition to the Company’s intangible technology asset within the balance sheet and will be amortized over the estimated remaining life of the technology asset. As of June 30, 2014, the option payment of $2.5 million had not yet been paid and was therefore accrued for with a corresponding asset recorded in Other assets on the Balance Sheet.
	Legal Matters
	The Company may periodically become subject to legal proceedings and claims arising in connection with its business. The Company is not currently involved in any legal proceedings nor are there any claims against the Company pending.
	The Company sells its products in various jurisdictions and is subject to federal, state and local taxes including, where applicable, sales and use tax. While the Company believes that it has properly paid or accrued for all such taxes based on its interpretation of applicable law, tax laws are complex and interpretations differ. Periodically, the Company may be audited by taxing authorities, and it is possible that additional assessments may be made in the future.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	10. FAIR VALUE MEASUREMENTS
	The Company’s financial instruments consist of cash and cash equivalents, trade accounts receivable, accounts payable, short-term deferred payments, deferred payments, notes payable, accrued expenses and Convertible Preferred Stock Warrants. The carrying amounts of cash and cash equivalents, trade accounts receivable, accounts payable, short-term deferred payments and accrued expenses approximate their fair values because of the short-term nature of the instruments, or, in the case of the deferred payments and notes payable, because the interest rates the Company believes it could obtain for similar borrowings is similar to its existing interest rates. The following table summarizes the fair value information for the Company’s cash held in money market deposit accounts and its Convertible Preferred Stock Warrants at June 30, 2014 and December 31, 2013 (amounts in thousands):
						Fair value measurements using:
			Carrying			Quoted Prices in			Significant Other		Significant
			Value			Active Markets			Observable Inputs		Unobservable
						(Level 1)			(Level 2)		Inputs (Level 3)
	As of June 30, 2014
	Financial Assets:
	Money market deposit accounts		$	25,017		$	25,017			—		—
	Financial Liabilities:
	Convertible Preferred Stock Warrants		$	1,142			—			—	$	1,142
	As of December 31, 2013
	Financial Assets:
	Money market deposit accounts		$	25,470		$	25,470			—		—
	Financial Liabilities:
	Convertible Preferred Stock Warrants		$	212			—			—	$	212
	Some of the Company’s cash and cash equivalents are held in money market deposit accounts which are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices or market prices for similar securities.
	Per ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”) the Convertible Preferred Stock Warrants are classified within Level 3 of the fair value hierarchy as they are revalued to their fair value, using the Black-Scholes option-pricing model, at each reporting period end and any change in fair value is reflected in the Statement of Operations and Comprehensive Loss. There have been no transfers between levels during the reporting period.
	Using the Black-Scholes option-pricing model for warrants outstanding at June 30, 2014 and December 31, 2013, the Company applied the following assumptions:
			As of June 30,			As of December 31,
			2014			2013
	Series B Warrants
	Expected life in years(1)			2.2			0.5
	Interest rate			0.47	%		0.1	%
	Volatility			60	%		60	%
	Dividend yield			—			—
	Series E Warrants
	Expected life in years(1)			9.4			0.5
	Interest rate			2.53	%		0.1	%
	Volatility			60	%		60	%
	Dividend yield			—			—
	-1	See Note 2 for details regarding the change in expected life from December 31, 2013 to June 30, 2014
	Reasonable changes in the assumptions used to value the warrants would not have a material impact on the liability balance at the end of any reporting period presented.
	The table below provides a summary of the changes in the Convertible preferred stock warrant liability during the six months ended June 30, 2014 and the six months ended June 30, 2013 (amounts in thousands):
			For the Six Months Ended June 30,
			2014			2013
	Balance at beginning of period		$	212		$	100
	Issuance of Series A Warrants			—			6,674
	Increase in Series E warrant shares			135			—
	Change in fair value of warrants(1)			795			575
	Balance at end of period		$	1,142		$	7,349
	-1	Includes $666,000 of prior period fair value adjustments as discussed in Note 2 above.

Convertible_Preferred_Stock_an

Convertible Preferred Stock and Stockholders' Deficit	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Convertible Preferred Stock and Stockholders' Deficit	'
	11. CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
	The Company has multiple classes of preferred stock for which shares are authorized, issued and outstanding. There were no issuances of Convertible Preferred Stock in the six months ended June 30, 2014. During the six months ended June 30, 2013, the Company issued 17,111,567 shares of Series E convertible preferred stock as well as warrants to purchase 171,118 shares of Series A and Series A-1 Convertible Preferred Stock. The warrants were subsequently exercised in the three months ended September 30, 2013. During the six months ended June 30, 2013, the Company had shares of Series A Convertible Preferred Stock outstanding which, along with the additional Series A and Series A-1 shares issued upon exercise of Series A and Series A-1 warrants in the three months ended September 30, 2013, were subsequently converted into Common Stock in the fourth quarter of 2013. No such shares of Series A Convertible Preferred Stock were authorized, issued or outstanding as of and for the six months ended June 30, 2014. The dividend rights, voting rights, liquidation rights, conversion rights and registration rights of the classes of preferred stock for which shares are authorized are indicated below.
	Dividend rights
	Holders of issued and outstanding shares of Series B, Series C, Series D and Series E are entitled to annual cash dividends of 8% based on the original issuance price when and if declared by the Company’s Board of Directors. The original issuance price, adjusted in the event of a stock split, stock dividends, recapitalizations or the like as defined, is $1.00 for Series B, $1.325 for Series C, $1.461 for Series D and $1.275 for Series E. No dividend can be declared or paid for other stock classes until the preferred dividend for Series B, Series C, Series D and Series E has been paid.
	Dividends payable to holders of Series B, Series C, Series D and Series E are not cumulative, and no right will accrue to holders of such Convertible Preferred Stock if dividends are not declared.
	No dividends can be declared or paid on Common Stock unless all dividends, accrued or declared, on the Convertible Preferred Stock have been paid in full.
	Voting rights
	Each holder of Convertible Preferred Stock, is entitled to vote with Common A stockholders on an “as if” converted basis.
	The Board of Directors consists of up to nine members.
	Holders of Series B, voting as a single class, are entitled to elect four directors. Holders of Series D, voting as a single class, are entitled to elect one director. Holders of all voting stock classes are entitled to elect four directors.
	Holders of Common B do not have voting rights.
	Liquidation rights
	In the event of a liquidation or dissolution of the Company, the holders of Series E, in preference to and priority to all other stockholders, are entitled to be paid, out of the assets of the Company, the original issuance price plus any declared but unpaid dividends. After payment to holders of Series E, in preference to and priority to all other stockholders (except Series E stockholders), the holders of Series D are entitled to be paid, out of the assets of the Company, the original issuance price plus any declared but unpaid dividends. After payment to holders of Series E and Series D, and from any remaining assets legally available, holders of Series B and Series C will be paid the original issuance price plus any declared but unpaid dividends.
	A liquidation event will be deemed to have occurred under certain situations if the Company experiences a change in control, merges with another company or sells substantially all of its assets. As the holders of the Company’s Convertible Preferred Stock collectively control the Board, such contingent liquidation events cause the Convertible Preferred Stock to be classified as mezzanine equity.
	Conversion rights
	Each share of Convertible Preferred Stock is convertible at the option of the holder, without payment of additional consideration. Under certain defined situations, including the closing of an initial public offering, approved by the holders of Series B, Series C, Series D and Series E voting together as a single class on an as-converted to Common Stock basis, Convertible Preferred Stock will automatically convert to Common Stock. Typically, each share of Convertible Preferred Stock will convert into approximately 0.0906 shares of Common Stock. Shares of Series D will convert into approximately 0.0937 shares of Common Stock per share of Series D as a result of exercising their anti-dilution rights provision in conjunction with the Series E share issuance in November 2013.
	Registration rights
	Upon the expiration of the 180-day lock-up period that commenced on July 16, 2014, holders of at least 51% of common stock issuable or issued upon the conversion of Convertible Preferred Stock may require that the the Company file a registration statement under the Securities Act covering the registration of such shares of common stock issued or issuable upon the conversion of Convertible Preferred Stock. These rights are provided under the terms of an investor rights agreement between the Company and the holders of the Company’s Convertible Preferred Stock and Convertible Preferred Stock Warrants. However, the Company is only required to register such shares of common stock issued or issuable upon the conversion of Convertible Preferred Stock pursuant to such a request if the offering results in net proceeds of at least $30 million.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	12. STOCK-BASED COMPENSATION
	Under the Roka Bioscience, Inc. 2009 Equity Incentive Plan (the “2009 Plan”), as amended on June 13, 2013, incentive and non-qualified stock options and restricted stock may be granted for up to a maximum of 2,028,850 shares to employees, consultants and directors of the Company.
	Stock options and shares of restricted stock granted under the 2009 Plan have a maximum contractual term of ten years from the date of grant and generally vest over four years. For stock options, the exercise price may not be less than the fair value of the stock on the grant date.
	The Company recognized stock compensation expense as follows (amounts in thousands):
		For the Three Months Ended June 30,					For the Six Months Ended June 30,
		2014			2013		2014		2013
	Stock options	$	65		$	54	$	133	$	114
	Restricted stock	$	198		$	120	$	391	$	240
	The Company granted approximately 4,000 stock options and 86,000 stock options during the six months ended June 30, 2014 and 2013, respectively, valued at approximately $18,000 and $59,000, respectively.
	The Company determines the fair value of stock option awards at the date of grant using a Black-Scholes valuation model. This model requires the Company to make assumptions and judgments on the expected volatility, dividend yield, the risk-free interest rate and the expected term of the stock options. The following ranges of assumptions were utilized for stock options granted:
		For the Six Months Ended June 30,
		2014		2013
	Expected life in years	5.9-6.0		5.7-6.0
	Interest rate	2.01%-2.04%		0.99%-1.06%
	Volatility	60%		70%
	Dividend yield	—		—
	The Company estimates the expected life of its employee stock options using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates are based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The expected stock price volatility rates are based on average historical volatilities of the common stock of a group of public companies in similar industries. The Company has no history or expectations of paying dividends on its Common Stock and therefore uses a zero percent dividend yield in the Black-Scholes option pricing model.

Warrants_for_Convertible_Prefe

Warrants for Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Warrants for Convertible Preferred Stock	'
	13. WARRANTS FOR CONVERTIBLE PREFERRED STOCK
	The Company has Series B Warrants outstanding which allow their holders to purchase 2,480,000 shares of Series B at an exercise price of $1.00 per share. The warrants expire in September 2016, whereupon any warrants that remain unexercised will be exercised automatically in whole in a cashless exercise resulting in an issuance, to the holders of the warrants, the number of shares with a value equal to the intrinsic value of the warrants at the time of expiry.
	In connection with the closing of the loan and security agreements discussed in Note 8, the Company issued warrants to Comerica and TriplePoint to purchase up to an aggregate of 352,941 shares of Series E with an exercise price of $1.28. Upon issuance, the Company recorded liabilities on the Balance Sheet of approximately $28,000 and $55,000 for the warrants issued to Comerica and TriplePoint, respectively. The initial fair value of the warrant issued to Comerica of approximately $28,000 was deemed a discount on the debt issued by Comerica and is being accreted to interest expense over the term of the Comerica Loan. The initial fair value of the warrants issued to TriplePoint of approximately $55,000 is included in the $153,000 of debt issuance costs which were capitalized in Other assets on the Balance Sheet and will be amortized to Interest expense. In connection with the borrowings made under the second tranche in March 2014, one of the TriplePoint warrants became exercisable for an additional 156,863 shares of Series E. The second TriplePoint warrant will become exercisable for up to an additional 156,863 shares of Series E, based on borrowings under the third tranche. The initial fair value of approximately $135,000 for the warrants issued to TriplePoint in connection with the borrowings under the second tranche was deemed a discount on the debt issued by TriplePoint and is being accreted to interest expense over the term of the second tranche.
	See Note 10 for the assumptions used to determine the fair value of the Convertible preferred stock warrant liability as of June 30, 2014 and December 31, 2013, respectively and a summary of the changes in the Convertible preferred stock warrant liability for the six months ended June 30, 2014 and 2013.

Net_Loss_per_Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	14. NET LOSS PER SHARE
	Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. The weighted-average common shares outstanding excludes unvested restricted stock which although such shares are legally issued and outstanding, are not required to share in losses of the Company and are therefore excluded from the net loss per share calculation. Diluted net loss per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, Convertible Preferred Stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.
		For the Three Months Ended June 30,									For the Six Months Ended June 30,
		2014						2013			2014						2013
		Common A			Common B			Common A			Common A			Common B			Common A
	Net loss applicable to common shareholders (thousands)	$	(7,326	)	$	(24	)	$	(7,942	)	$	(15,664	)	$	(53	)	$	(15,657	)
	Deemed dividend (thousands)		—			—			184			—			—			184
	Net loss applicable to common shareholders for computing loss per share (thousands)	$	(7,326	)	$	(24	)	$	(7,758	)	$	(15,664	)	$	(53	)	$	(15,473	)
	Basic and diluted weighted average common shares outstanding		649,453			2,145			486,184			629,475			2,145			453,768
	Basic and diluted loss per share	$	(11.28	)	$	(11.28	)	$	(15.96	)	$	(24.88	)	$	(24.88	)	$	(34.10	)
	As the Company incurred a loss for the three months and six months ended June 30, 2014 and 2013, all unvested restricted stock awards were excluded from the calculation of basic net loss per share and all potential Common A shares issuable for Convertible Preferred Stock, stock options and warrants were excluded from the calculation of diluted net loss per share, as the effect of including them would have been anti-dilutive. Had the Company not incurred a loss, the dilutive effect of the unvested restricted stock awards on basic weighted average common shares outstanding and the dilutive effect of potential Common A shares issuable for Convertible Preferred Stock, stock options and warrants on the weighted-average number of Common A shares outstanding would have been as follows:
		For the Three Months Ended June 30,									For the Six Months Ended June 30,
		2014						2013			2014						2013
		Common A			Common B			Common A			Common A			Common B			Common A
	Basic weighted average shares outstanding		649,453			2,145			486,184			629,475			2,145			453,768
	Dilutive effect of unvested restricted stock		273,480			—			15,492			243,369			—			8,948
	Basic weighted average shares outstanding had the Company not incurred a loss		922,933			2,145			501,676			872,844			2,145			462,716
	Dilutive effect of Convertible Preferred Stock		10,494,458			—			7,931,430			10,494,458			—			7,812,067
	Dilutive effect of stock options		382,359			—			96,586			376,052			—			48,293
	Diluted weighted average shares outstanding had the Company not incurred a loss		11,799,750			2,145			8,529,692			11,743,354			2,145			8,323,076

Segment_Information

Segment Information	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	17. SEGMENT INFORMATION
	The Company operates in a single reportable segment. During the six months ended June 30, 2014, the Company had four customers which each generated more than 10% of the Company’s revenues. These four customers accounted for revenues of approximately $706,000, $429,000, $421,000 and $247,000, respectively. During the six months ended June 30, 2013, the Company had three customers which each generated more than 10% of the Company’s revenues. These three customers accounted for revenues of approximately $290,000, $286,000 and $101,000, respectively.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	18. SUBSEQUENT EVENTS
	On July 22, 2014, the Company closed a $60.0 million initial public offering in which 5,000,000 shares of common stock were sold at $12.00 per share. The Company received approximately $53.4 million of net proceeds from the offering after deducting underwriting discounts, commissions and estimated offering expenses previously paid or payable by the Company. In connection with the closing of the IPO, all shares of Common A and Common B were converted into a new class of common stock on a 1:1 basis and all shares of Convertible Preferred Stock were converted into the new class of common stock at their respective conversion ratios. Additionally, the Company chose to exercise its royalty reduction option pursuant to the amendment to the Company’s license agreement with Gen-Probe. Subsequent to the closing of the IPO, the Company issued 865,063 shares of common stock to Gen-Probe and made a payment of $8.0 million to Gen-Probe as a result of exercising its royalty reduction option. See Note 9 for further details. Upon the completion of the initial public offering, $2.2 million of registration expenses recorded in Prepaid expenses and other current assets on the Balance Sheet as of June 30, 2014 was reclassified to equity as a reduction of the proceeds of the offering.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed financial statements of Roka Bioscience, Inc. have been prepared by the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these condensed notes to the unaudited financial statements should be read in conjunction with the 2013 audited financial statements and notes thereto prepared in accordance with U.S. GAAP. The unaudited financial statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited financial statements for the year ended December 31, 2013. The condensed Balance Sheet as of December 31, 2013 was derived from the Company’s audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. There have been no changes to the Company’s significant accounting policies since December 31, 2013. The unaudited financial statements reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods presented. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other future annual or interim period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited financial statements included in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission (the “SEC”) on July 16, 2014 (the “Prospectus”).
	Previously, the Company calculated the fair value of its convertible preferred stock warrants outstanding using a time period based upon an estimated liquidation date. During the three months ended March 31, 2014, it was determined that a liquidation date cannot be reasonably estimated, nor do they automatically expire upon a liquidation event such as an initial public offering, and consequently the life used to value these warrants should reflect the expiration date of each warrant. As a result of this change in estimate, during the three months ended March 31, 2014 the Company recognized the following prior period expenses: approximately $435,000 related to the change in fair value of warrants, approximately $26,000 of interest expense and approximately $77,000 of other expenses as a result of the change in calculation of the fair value of warrants. Additionally, this change in valuation resulted in a reduction of notes payable of approximately $77,000, deemed to be an additional debt discount which will be accreted to notes payable over the life of the loan with a corresponding charge to interest expense. Furthermore, the change in valuation resulted in an increase in our deferred financing costs of $77,000 which was expensed in the six months ended June 30, 2014. Management does not believe this adjustment is material to the current or prior periods.
Common A and Common B Reverse Stock Split	'
	Common A and Common B Reverse Stock Split
	In July 2014, the Company’s board of directors authorized and the Company’s shareholders approved an 11.04:1 reverse stock split of the Company’s Class A common stock (“Common A”) and Class B common stock (“Common B”), together referred to as “Common Stock”, effective on July 3, 2014. In addition, effective on the date of the Common Stock reverse stock split, the conversion ratio of Series B Convertible Preferred Stock (“Series B”), Series C Convertible Preferred Stock (“Series C”), Series D Convertible Preferred Stock (“Series D”) and Series E Convertible Preferred Stock (“Series E”) collectively referred to as “Convertible Preferred Stock” was adjusted by a factor of 11.04. Each share of Series B, Series C and Series E will be convertible into approximately 0.0906 shares of Common Stock and each share of Series D will be convertible into approximately 0.0937 shares of Common Stock. The Company’s historical share and per share information have been retroactively adjusted to give effect to this reverse split and corresponding change in conversion ratio.
New Accounting Pronouncements	'
	New Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. ASU 2014-09 provides companies with two implementation methods. Companies can choose to apply the standard retrospectively to each prior reporting period presented (full retrospective application) or retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early application is not permitted. The Company is currently in the process of evaluating the impact this new guidance will have on the Company.

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Summary of Net Inventories	'
	The following table provides details of the Company’s net inventories (amounts in thousands):
		As of June 30,		As of December 31,
		2014		2013
	Raw materials	$	1,674	$	1,846
	Work in process		93		—
	Finished goods		2,939		2,033
		$	4,706	$	3,879

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Schedule of Property and Equipment	'
	The following table provides details of the Company’s property and equipment (amounts in thousands):
		As of June 30,			As of December 31,
		2014			2013
	Atlas instruments	$	10,192		$	10,330
	Manufacturing equipment		2,801			2,801
	Laboratory equipment		2,967			2,923
	Computer and office equipment		1,427			1,388
	Leasehold improvements		1,272			1,272
	Software		1,113			1,106
	Total property and equipment	$	19,772		$	19,820
	Less: Accumulated depreciation		(6,514	)		(5,310	)
	Total	$	13,258		$	14,510
Schedule of Expenses for Depreciation of Property and Equipment	'
	Expenses for depreciation of property and equipment were incurred as follows (amounts in thousands):
		For the Three Months Ended June 30,						For the Six Months Ended June 30,
		2014			2013			2014		2013
	Depreciation expense	$	625		$	558		$	1,244	$	1,095

Accrued_Expenses_Tables

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2014
Payables And Accruals [Abstract]	'
Summary of Accrued Expenses	'
	The following table provides details of the Company’s accrued expenses (amounts in thousands):
		As of June 30,		As of December 31,
		2014		2013
	Employee related	$	1,217	$	888
	Professional services		963		1,328
	Other		3,307		165
	Total accrued expenses	$	5,487	$	2,381

Deferred_Payments_Tables

Deferred Payments (Tables)	6 Months Ended
	Jun. 30, 2014
Other Liabilities Disclosure [Abstract]	'
Summary of Amounts Deferred under Supply Agreement	'
	The following table summarizes the amounts deferred under this agreement (amounts in thousands):
		As of June 30,			As of December 31,
		2014			2013
	Current
	Deferred payments, gross	$	923		$	759
	Imputed interest		(402	)		(420	)
	Deferred payments, net	$	521		$	339
	Long-term
	Deferred payments, gross	$	3,868		$	4,053
	Imputed interest		(652	)		(848	)
	Deferred payments, net	$	3,216		$	3,205

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Cash Held in Money Market Deposit Accounts and its Convertible Preferred Stock Warrants	'
	The following table summarizes the fair value information for the Company’s cash held in money market deposit accounts and its Convertible Preferred Stock Warrants at June 30, 2014 and December 31, 2013 (amounts in thousands):
						Fair value measurements using:
			Carrying			Quoted Prices in			Significant Other		Significant
			Value			Active Markets			Observable Inputs		Unobservable
						(Level 1)			(Level 2)		Inputs (Level 3)
	As of June 30, 2014
	Financial Assets:
	Money market deposit accounts		$	25,017		$	25,017			—		—
	Financial Liabilities:
	Convertible Preferred Stock Warrants		$	1,142			—			—	$	1,142
	As of December 31, 2013
	Financial Assets:
	Money market deposit accounts		$	25,470		$	25,470			—		—
	Financial Liabilities:
	Convertible Preferred Stock Warrants		$	212			—			—	$	212
Black-Scholes Option-Pricing Model for Warrants Outstanding	'
	Using the Black-Scholes option-pricing model for warrants outstanding at June 30, 2014 and December 31, 2013, the Company applied the following assumptions:
			As of June 30,			As of December 31,
			2014			2013
	Series B Warrants
	Expected life in years(1)			2.2			0.5
	Interest rate			0.47	%		0.1	%
	Volatility			60	%		60	%
	Dividend yield			—			—
	Series E Warrants
	Expected life in years(1)			9.4			0.5
	Interest rate			2.53	%		0.1	%
	Volatility			60	%		60	%
	Dividend yield			—			—
	-1	See Note 2 for details regarding the change in expected life from December 31, 2013 to June 30, 2014
Summary of the Changes in the Convertible Preferred Stock Warrant Liability	'
	The table below provides a summary of the changes in the Convertible preferred stock warrant liability during the six months ended June 30, 2014 and the six months ended June 30, 2013 (amounts in thousands):
			For the Six Months Ended June 30,
			2014			2013
	Balance at beginning of period		$	212		$	100
	Issuance of Series A Warrants			—			6,674
	Increase in Series E warrant shares			135			—
	Change in fair value of warrants (1)			795			575
	Balance at end of period		$	1,142		$	7,349
	-1	Includes $666,000 of prior period fair value adjustments as discussed in Note 2 above.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Recognized Stock Compensation Expense	'
	The Company recognized stock compensation expense as follows (amounts in thousands):
		For the Three Months Ended June 30,					For the Six Months Ended June 30,
		2014			2013		2014		2013
	Stock options	$	65		$	54	$	133	$	114
	Restricted stock	$	198		$	120	$	391	$	240
Ranges of Assumptions were Utilized for Stock Options Granted	'
	The following ranges of assumptions were utilized for stock options granted:
		For the Six Months Ended June 30,
		2014		2013
	Expected life in years	5.9-6.0		5.7-6.0
	Interest rate	2.01%-2.04%		0.99%-1.06%
	Volatility	60%		70%
	Dividend yield	—		—

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Basic and Diluted Net Loss per Share Applicable to Common Stockholders	'
	For purposes of the diluted net loss per share calculation, Convertible Preferred Stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.
		For the Three Months Ended June 30,									For the Six Months Ended June 30,
		2014						2013			2014						2013
		Common A			Common B			Common A			Common A			Common B			Common A
	Net loss applicable to common shareholders (thousands)	$	(7,326	)	$	(24	)	$	(7,942	)	$	(15,664	)	$	(53	)	$	(15,657	)
	Deemed dividend (thousands)		—			—			184			—			—			184
	Net loss applicable to common shareholders for computing loss per share (thousands)	$	(7,326	)	$	(24	)	$	(7,758	)	$	(15,664	)	$	(53	)	$	(15,473	)
	Basic and diluted weighted average common shares outstanding		649,453			2,145			486,184			629,475			2,145			453,768
	Basic and diluted loss per share	$	(11.28	)	$	(11.28	)	$	(15.96	)	$	(24.88	)	$	(24.88	)	$	(34.10	)
Calculation of Weighted Average Shares Outstanding , Event of Not Incurring Loss	'
	As the Company incurred a loss for the three months and six months ended June 30, 2014 and 2013, all unvested restricted stock awards were excluded from the calculation of basic net loss per share and all potential Common A shares issuable for Convertible Preferred Stock, stock options and warrants were excluded from the calculation of diluted net loss per share, as the effect of including them would have been anti-dilutive. Had the Company not incurred a loss, the dilutive effect of the unvested restricted stock awards on basic weighted average common shares outstanding and the dilutive effect of potential Common A shares issuable for Convertible Preferred Stock, stock options and warrants on the weighted-average number of Common A shares outstanding would have been as follows:
		For the Three Months Ended June 30,									For the Six Months Ended June 30,
		2014						2013			2014						2013
		Common A			Common B			Common A			Common A			Common B			Common A
	Basic weighted average shares outstanding		649,453			2,145			486,184			629,475			2,145			453,768
	Dilutive effect of unvested restricted stock		273,480			—			15,492			243,369			—			8,948
	Basic weighted average shares outstanding had the Company not incurred a loss		922,933			2,145			501,676			872,844			2,145			462,716
	Dilutive effect of Convertible Preferred Stock		10,494,458			—			7,931,430			10,494,458			—			7,812,067
	Dilutive effect of stock options		382,359			—			96,586			376,052			—			48,293
	Diluted weighted average shares outstanding had the Company not incurred a loss		11,799,750			2,145			8,529,692			11,743,354			2,145			8,323,076

Business_Overview_Additional_I

Business Overview (Additional Information) (Detail) (Subsequent Event [Member], USD $)	1 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2014
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Net proceeds from initial public offering	$53.40

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended		1 Months Ended
	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2014	Jul. 31, 2014	Jul. 31, 2014	Jul. 31, 2014
			Common Class A and Class B [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
				Convertible Preferred Stock [Member]	Series B, Series C and Series E Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'
Fair value of warrants	$435,000	'	'	'	'	'
Interest expense	26,000	'	'	'	'	'
Other expenses	77,000	'	'	'	'	'
Reduction of notes payable	77,000	'	'	'	'	'
Increase in deferred financing costs	'	$77,000	'	'	'	'
Reverse stock split of common stock	'	'	'11.04:1 reverse stock split	'	'	'
Reverse stock split, conversion ratio	'	'	'	11.04	0.0906	0.0937

Inventories_Summary_of_Net_Inv

Inventories - Summary of Net Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$1,674	$1,846
Work in process	93	'
Finished goods	2,939	2,033
Inventory, net	$4,706	$3,879

Property_and_Equipment_Schedul

Property and Equipment - Schedule of Property and Equipment (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	$19,772	$19,820
Less: Accumulated depreciation	-6,514	-5,310
Property and Equipment, Net	13,258	14,510
Atlas Instrument [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	10,192	10,330
Less: Accumulated depreciation	-900	-500
Property and Equipment, Net	9,300	9,800
Manufacturing Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	2,801	2,801
Laboratory Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	2,967	2,923
Computers and Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	1,427	1,388
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	1,272	1,272
Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	$1,113	$1,106

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Accumulated depreciation	$6,514	$5,310
Cost of equipment on lease or held for lease, net of accumulated depreciation	13,258	14,510
Atlas Instrument [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Accumulated depreciation	900	500
Cost of equipment on lease or held for lease, net of accumulated depreciation	$9,300	$9,800

Property_and_Equipment_Schedul1

Property and Equipment - Schedule of Expenses for Depreciation of Property and Equipment (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property Plant And Equipment Useful Life And Values [Abstract]	'	'	'	'
Depreciation expense	$625	$558	$1,244	$1,095

Accrued_Expenses_Summary_of_Ac

Accrued Expenses - Summary of Accrued Expenses (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities Current And Noncurrent [Abstract]	'	'
Employee related	$1,217	$888
Professional services	963	1,328
Other	3,307	165
Total accrued expenses	$5,487	$2,381

Accrued_Expenses_Additional_In

Accrued Expenses - Additional Information (Detail) (USD $)	0 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Accrued Expenses [Line Items]	'	'
Issuance costs	$430,000	$526,000
Gen- Probe [Member]	'	'
Accrued Expenses [Line Items]	'	'
License agreement option payment	$2,500,000	'

Deferred_Payments_Additional_I

Deferred Payments - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Other Liabilities [Line Items]	'	'	'	'
Deferred payment period	'	'	'54 months	'
Non-cash interest expense related to the deferred payments	$106,000	$84,000	$214,000	$164,000
Minimum [Member]	'	'	'	'
Other Liabilities [Line Items]	'	'	'	'
Debt instrument effective percentage	9.90%	'	9.90%	'
Maximum [Member]	'	'	'	'
Other Liabilities [Line Items]	'	'	'	'
Debt instrument effective percentage	11.20%	'	11.20%	'
Gen- Probe [Member]	'	'	'	'
Other Liabilities [Line Items]	'	'	'	'
Supply agreement date	'	'	'2011-05	'

Deferred_Payments_Summary_of_A

Deferred Payments - Summary of Amounts Deferred under Supply Agreement (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current	'	'
Deferred payments, gross	$923,000	$759,000
Imputed interest	-402,000	-420,000
Deferred payments, net	521,000	339,000
Long-term	'	'
Deferred payments, gross	3,868	4,053
Imputed interest	-652,000	-848,000
Deferred payments, net	$3,216,000	$3,205,000

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Nov. 30, 2013
Line of Credit Facility [Line Items]	'	'	'
Loan and security agreement, maximum borrowing capacity	'	'	$15,000,000
Number of loans	2	'	'
Number of tranches	3	'	'
Maximum borrowing capacity per tranches	'	'	5,000,000
Loan and security agreement, minimum interest rate	5.75%	'	'
Loan and security agreement, interest payment description	'Each tranche under the TriplePoint Loan is repayable over 36 months from the borrowing date with an interest-only period of nine months for the second tranche and six months for the third tranche (or 12 months for each tranche upon election by the Company to extend the interest only period)	'	'
Loan and security agreement, maximum interest rate	9.00%	'	'
Loan and security agreement, period of repayment	'36 months	'	'
Convertible Preferred Stock Series E [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
No of warrants issued to purchase shares of series E	352,941	'	'
Share exercise price value	$1.28	'	'
Interest Only Period [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Loan and security agreement, minimum interest rate	6.25%	'	'
Loan and security agreement, maximum interest rate	9.50%	'	'
Second Tranche [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Additional shares for warrants exercisable	'	156,863	'
Third Tranche [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Revenue	10,000,000	'	'
Comerica Loan [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Loan and security agreement, maximum borrowing capacity	'	'	5,000,000
Loan and security agreement, interest rate description	'Subject to a floor of the daily adjusting LIBOR rate plus 2.5%, plus 3.15%.	'	'
Loan and security agreement, interest rate at period end	6.40%	'	'
Accrued interest and equal principal payments periods	'23 months	'	'
Loan and security agreement, maturity period	'42 months	'	'
Loan and security agreement, maturity date	1-Jun-15	'	'
Loan and security agreement, interest payment description	'Company will make 23 consecutive monthly payments which will consist of accrued interest and equal principal payments in accordance with a 30-month amortization schedule. On the 24thmonth following the interest only period, the Company will make a lump sum payment for the remaining outstanding principal and interest due.	'	'
Net of expenses paid to Comerica	4,900,000	'	'
Debt issuance costs	76,000	'	'
Comerica Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Loan and security agreement, minimum interest rate	2.50%	'	'
Loan and security agreement, additional minimum interest rate	3.15%	'	'
TriplePoint Loan [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Loan and security agreement, maximum borrowing capacity	'	'	10,000,000
Loan and security agreement, interest rate description	'Prime Rate plus 5.75%, but not less than 9.0%	'	'
Loan and security agreement, interest rate description extends interest only period	'Prime Rate plus 6.25%, but not less than 9.5%.	'	'
Line of credit maturity term	'36 months	'	'
Debt issuance costs	153,000	'	'
Warrant liability	'	135,000	'
TriplePoint Loan [Member] | Notes Payable [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Value of warrants recorded for liability	'	5,000,000	'
TriplePoint Loan [Member] | Second Tranche [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Loan and security agreement, maximum borrowing capacity	5,000,000	5,000,000	'
Loan and security agreement, interest rate at period end	'	9.50%	'
TriplePoint Loan [Member] | Third Tranche [Member]	'	'	'
Line of Credit Facility [Line Items]	'	'	'
Loan and security agreement, maximum borrowing capacity	$5,000,000	'	'
Additional shares for warrants exercisable	'	156,863	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jan. 01, 2020	Jan. 01, 2018
			Gen- Probe [Member]	Gen- Probe [Member]	Gen- Probe [Member]
				Scenario, Forecast [Member]	Scenario, Forecast [Member]
Commitment And Contingencies [Line Items]	'	'	'	'	'
Option grant period	'	'	'	'	'
License agreement option payment	'	'	$2,500,000	'	'
Proceeds from option exercised	'	'	55,000,000	'	'
Description for term & settlement of related party transaction	'	'	'(i) within ten days of the closing of an IPO, the Company would issue 865,063 shares of common stock to Gen-Probe, (ii) within ten days of the closing of an IPO, the Company would make a cash payment of $8.0 million using a portion of the net proceeds from such IPO, (iii) on January 1, 2018, the Company would make a cash payment of $5.0 million and (iv) on January 1, 2020, the Company would make a cash payment of $5.0 million.	'	'
Shares of common stock issued	'	'	865,063	'	'
Cash payment for royalties	'	'	8,000,000	5,000,000	5,000,000
Additional milestone payments	'	'	6,000,000	'	'
Other assets	$2,823,000	$444,000	$2,500,000	'	'

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value of Cash Held in Money Market Deposit Accounts and its Convertible Preferred Stock Warrants (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Carrying Value [Member] | Money Market Deposit Accounts [Member]	'	'
Financial Assets:	'	'
Money market deposit accounts	$25,017	$25,470
Carrying Value [Member] | Convertible Preferred Stock Warrants [Member]	'	'
Financial Liabilities:	'	'
Convertible Preferred Stock Warrants	1,142	212
Quoted Prices in Active Markets (Level 1) [Member] | Money Market Deposit Accounts [Member]	'	'
Financial Assets:	'	'
Money market deposit accounts	25,017	25,470
Significant Unobservable Inputs (Level 3) [Member] | Convertible Preferred Stock Warrants [Member]	'	'
Financial Liabilities:	'	'
Convertible Preferred Stock Warrants	$1,142	$212

Fair_Value_Measurements_BlackS

Fair Value Measurements - Black-Scholes Option-Pricing Model for Warrants Outstanding (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Series B Warrants [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Expected life in years	'2 years 2 months 12 days	'6 months
Interest rate	0.47%	0.10%
Volatility	60.00%	60.00%
Dividend yield	'	'
Series E Warrants [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Expected life in years	'9 years 4 months 24 days	'6 months
Interest rate	2.53%	0.10%
Volatility	60.00%	60.00%
Dividend yield	'	'

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of the Changes in the Convertible Preferred Stock Warrant Liability (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Balance at beginning of period	$212	$100
Change in fair value of warrants	795	575
Balance at end of period	1,142	7,349
Series A Warrants [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Issuance of Series A Warrants	'	6,674
Series E Warrants [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Increase in Series E warrant shares	$135	'

Fair_Value_Measurements_Summar1

Fair Value Measurements - Summary of the Changes in the Convertible Preferred Stock Warrant Liability (Parenthetical) (Detail) (USD $)	3 Months Ended	6 Months Ended
	Mar. 31, 2014	Jun. 30, 2014
		Prior Period Adjustments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Fair value of warrants	$435,000	$666,000

Convertible_Preferred_Stock_an1

Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail) (USD $)

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

In Millions, except Share data, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2014

Directors

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series E Convertible Preferred Stock [Member]

Series E Convertible Preferred Stock [Member]

Series C, Series D And Series E Preferred Stock [Member]

Series E Convertible Preferred Stock [Member]

Series A- And Series A-1 Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Directors

Directors

Directors

Temporary Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuances of Convertible Preferred Stock

0

37,200,000

37,200,000

12,090,672

12,090,672

32,511,979

32,511,979

32,934,700

32,934,700

'

17,111,567

'

0

Warrants to purchase shares

'

'

'

'

'

'

'

'

'

'

'

171,118

'

Series A Convertible Preferred Stock, shares authorized

'

39,680,000

39,680,000

12,090,672

12,090,672

32,511,979

32,511,979

33,601,367

33,601,367

'

'

'

0

Series A Convertible Preferred Stock, shares outstanding

'

37,200,000

37,200,000

12,090,672

12,090,672

32,511,979

32,511,979

32,934,700

32,934,700

'

'

'

0

Issuance price per share

'

$1

'

$1.32

'

$1.46

'

$1.27

'

'

'

'

'

Dividend rate

'

8.00%

'

8.00%

'

8.00%

'

8.00%

'

'

'

'

'

Number of Directors

9

4

'

'

'

1

'

'

'

4

'

'

'

Shares convert into common stock

0.0906

'

'

'

'

0.0937

'

'

'

'

'

'

'

Lock-up period

'180 days

'

'

'

'

'

'

'

'

'

'

'

'

Commencement of lock-up period

16-Jul-14

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate offering price

$30

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of registrable securities

51.00%

'

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock options granted, shares	4,000	86,000
Stock options granted, value	$18,000	$59,000
Dividend yield	0.00%	'
2009 Equity Incentive Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Maximum contractual term of restricted stock granted	'10 years	'
Contractual term of restricted stock vested	'4 years	'
2009 Equity Incentive Plan [Member] | Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock options and restricted shares granted	2,028,850	'

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Recognized Stock Compensation Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'	'
Stock options	$65	$54	$133	$114
Restricted stock	$198	$120	$391	$240

StockBased_Compensation_Ranges

Stock-Based Compensation - Ranges of Assumptions were Utilized for Stock Options Granted (Detail)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Volatility	60.00%	70.00%
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life in years	'5 years 10 months 24 days	'5 years 8 months 12 days
Interest rate	2.01%	0.99%
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life in years	'6 years	'6 years
Interest rate	2.04%	1.06%

Warrants_for_Convertible_Prefe1

Warrants for Convertible Preferred Stock - Additional Information (Detail) (USD $)	6 Months Ended		6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
		Second Tranche [Member]	Comerica Loan [Member]	TriplePoint Loan [Member]	Series B Warrants [Member]	Series E Warrants [Member]	Series E Warrants [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Warrants outstanding to purchase shares	'	'	'	'	2,480,000	352,941	'
Warrants outstanding share exercise price	'	'	'	'	$1	$1.28	'
Warrants expiration date	'2016-09-30	'	'	'	'	'	'
Warrants issued as payments	'	'	$28,000	$55,000	'	'	'
Debt issuance costs	'	'	'	153,000	'	'	'
Additional issues shares	'	156,863	'	'	'	'	'
Additional issues shares value	'	'	'	'	'	'	$135,000

Net_Loss_Per_Share_Schedule_of

Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share Applicable to Common Stockholders (Detail) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Earnings Per Share Basic And Diluted [Line Items]	'	'	'	'	'
Net loss applicable to common shareholders for computing loss per share	($7,349)	($7,942)	($15,716)	($15,656)	($29,578)
Basic and diluted weighted average common shares outstanding	651,598	486,184	631,620	453,768	'
Basic and diluted loss per share	($11.28)	($15.96)	($24.88)	($34.10)	'
Series A Common Stock [Member]	'	'	'	'	'
Earnings Per Share Basic And Diluted [Line Items]	'	'	'	'	'
Net loss applicable to common shareholders	-7,326	-7,942	-15,664	-15,657	'
Deemed dividend	'	184	'	184	'
Net loss applicable to common shareholders for computing loss per share	-7,326	-7,758	-15,664	-15,473	'
Basic and diluted weighted average common shares outstanding	649,453	486,184	629,475	453,768	'
Basic and diluted loss per share	($11.28)	($15.96)	($24.88)	($34.10)	'
Series B Common Stock [Member]	'	'	'	'	'
Earnings Per Share Basic And Diluted [Line Items]	'	'	'	'	'
Net loss applicable to common shareholders	-24	'	-53	'	'
Net loss applicable to common shareholders for computing loss per share	($24)	'	($53)	'	'
Basic and diluted weighted average common shares outstanding	2,145	'	2,145	'	'
Basic and diluted loss per share	($11.28)	'	($24.88)	'	'

Net_Loss_Per_Share_Calculation

Net Loss Per Share - Calculation of Weighted Average Shares Outstanding , Event of Not Incurring Loss (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Series A Common Stock [Member]	'	'	'	'
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Basic weighted average shares outstanding	649,453	486,184	629,475	453,768
Dilutive effect of unvested restricted stock	273,480	15,492	243,369	8,948
Basic weighted average shares outstanding had the Company not incurred a loss	922,933	501,676	872,844	462,716
Dilutive effect of Convertible Preferred Stock	10,494,458	7,931,430	10,494,458	7,812,067
Dilutive effect of stock options	382,359	96,586	376,052	48,293
Diluted weighted average shares outstanding had the Company not incurred a loss	11,799,750	8,529,692	11,743,354	8,323,076
Series B Common Stock [Member]	'	'	'	'
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Basic weighted average shares outstanding	2,145	'	2,145	'
Basic weighted average shares outstanding had the Company not incurred a loss	2,145	'	2,145	'
Diluted weighted average shares outstanding had the Company not incurred a loss	2,145	'	2,145	'

Segment_Information_Additional

Segment Information - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
	Customer	Customer
	Segment
Segment Reporting Information [Line Items]	'	'
Number of customers accounted for more than 10% of revenues	4	3
Number of reportable segments	1	'
Customer One [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues of major customer	706,000	290,000
Customer Two [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues of major customer	429,000	286,000
Customer Three [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues of major customer	421,000	101,000
Customer Four [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues of major customer	247,000	'
Revenue[Member]	'	'
Segment Reporting Information [Line Items]	'	'
Concentration risk percentage	10.00%	10.00%

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jul. 31, 2014	Jun. 30, 2014	Jul. 22, 2014	Jul. 22, 2014	Jun. 30, 2014
			Gen- Probe [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
						IPO [Member]	IPO [Member]	Gen- Probe [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'
Initial public offering	'	'	'	'	'	$60,000,000	'	'
Common Stock, shares issued	'	'	865,063	'	'	'	5,000,000	865,063
Common stock share price	'	'	'	'	'	'	$12	'
Net proceeds from offerings after deducting underwriting discounts, commissions	'	'	55,000,000	53,400,000	'	53,400,000	'	'
Common stock conversion description	'	'	'	'	'	'In connection with the closing of the IPO, all shares of Common A and Common B were converted into a new class of common stock on a 1:1 basis and all shares of Convertible Preferred Stock were converted into the new class of common stock at their respective conversion ratios.	'	'
Cash payment for royalties	'	'	8,000,000	'	'	'	'	8,000,000
Prepaid expenses and other current assets	$3,819,000	$2,437,000	'	'	$2,200,000	'	'	'